Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Kinetic-dynamic relations and individual responses to enalapril.

Donnelly R, Meredith PA, Elliott HL, Reid JL.

Hypertension. 1990 Mar;15(3):301-9.

2.

Factors determining the response to angiotensin-converting enzyme inhibitors in hypertension.

Reid JL, Donnelly R, Elliott HL, Meredith PA.

Clin Physiol Biochem. 1990;8 Suppl 1:1-5. Review.

PMID:
2257718
4.

Effects of enalapril, a new converting enzyme inhibitor, in hypertension.

Ferguson RK, Vlasses PH, Swanson BN, Mojaverian P, Hichens M, Irvin JD, Huber PB.

Clin Pharmacol Ther. 1982 Jul;32(1):48-53.

PMID:
6282527
5.

Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.

Lewis RA, Baker KM, Ayers CR, Weaver BA, Lehman MR.

J Cardiovasc Pharmacol. 1985;7 Suppl 1:S12-5.

PMID:
2580164
6.

Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

Ajayi AA, Hockings N, Reid JL.

Br J Clin Pharmacol. 1986 Apr;21(4):349-57.

7.
8.

Enalaprilat: an intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects.

Reams GP, Lal SM, Whalen JJ, Bauer JH.

J Clin Hypertens. 1986 Sep;2(3):245-53.

PMID:
3023555
9.

Additive effects of losartan and enalapril on blood pressure and plasma active renin.

Azizi M, Guyene TT, Chatellier G, Wargon M, Ménard J.

Hypertension. 1997 Feb;29(2):634-40.

11.

Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.

Gardner SY, Atkins CE, Sams RA, Schwabenton AB, Papich MG.

J Vet Intern Med. 2004 Mar-Apr;18(2):231-7.

12.

[The acute effects of the new angiotensin I-converting enzyme inhibitor, enalapril maleate, on blood pressure, plasma renin, aldosterone and kinins in hypertensive patients].

Gotoh M, Mizuno K, Hashimoto S, Kunii N, Fukuchi S.

Nihon Naibunpi Gakkai Zasshi. 1985 May 20;61(5):619-29. Japanese.

PMID:
2991035
13.

Relationship of serum ACE inhibition to oral dose of enalapril in normotensive volunteers.

Rouini M, Hamidi M, Ghayoumi A, Ismailpour A.

J Clin Pharm Ther. 2002 Apr;27(2):121-6.

PMID:
11975696
14.

T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans.

Petrov VV, Fagard RH, Lijnen PJ.

J Cardiovasc Pharmacol. 2001 Oct;38(4):578-83.

PMID:
11588528
15.

Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.

van den Meiracker AH, Admiraal PJ, Derkx FH, Kleinbloesem C, Man in 't Veld AJ, van Brummelen P, Mulder P, Schalekamp MA.

J Hypertens. 1993 Aug;11(8):831-8.

PMID:
8228207
16.

Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers.

Marzo A, Dal Bo L, Mazzucchelli P, Monti NC, Crivelli F, Ismaili S, Giusti A, Uhr MR.

Arzneimittelforschung. 2002;52(4):233-42.

PMID:
12040965
17.

A comparative pilot study of enalapril, a new converting enzyme inhibitor, and hydrochlorothiazide in essential hypertension.

Ferguson RK, Vlasses PH, Irvin JD, Swanson BN, Lee RB.

J Clin Pharmacol. 1982 Jul;22(7):281-9.

PMID:
6286734
18.

Blood pressure response to conventional and low-dose enalapril in chronic renal failure.

Elung-Jensen T, Heisterberg J, Kamper AL, Sonne J, Strandgaard S.

Br J Clin Pharmacol. 2003 Feb;55(2):139-46.

19.
20.

Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.

Schmitt F, Natov S, Martinez F, Lacour B, Hannedouche TP.

Clin Sci (Lond). 1996 Mar;90(3):205-13.

PMID:
8777826

Supplemental Content

Support Center